Key Takeaways U.S. pharma entered a rebound in 2025, with a $370B domestic investment pledge reshaping the industry. Tariff threats and MFN pricing deals pushed firms like Eli Lilly to expand U.S. manufacturing capacity. ETFs such as IHE offer diversified exposure to pharma's growth while reducing single-stock risks. The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a ...

Merck & Co. Inc. (NYSE:MRK) will not exercise its option for Evaxion A/S (NASDAQ:EVAX) Gonorrhea vaccine candidate EVX-B2.Gonorrhoea is a common, sexually transmitted infection caused by Neisseria gonorrhoeae.Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.Gonorrhea infects more than 80 million people worldwide each year. Despite decades of research, no vaccine has been approved to date. Preclinical studies demonstrate that EVX-B2 protects against ...

Philadelphia, Pennsylvania--(Newsfile Corp. - December 19, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

U.S. stocks were higher, with the Dow Jones index gaining more than 250 points on Friday.Shares of Carnival PLC (NYSE:CUK) rose sharply during Thursday's session after the company announced better-than-expected fourth-quarter adjusted EPS results and issuedFY26 adjusted EPS guidance above estimates.Carnival shares jumped 16.3% to $30.61 on Friday.Here are some other big stocks recording gains in today’s session.NovaBay Pharmaceuticals Inc (NYSE:NBY) shares jumped 45.1% to $4.28.Intuitive Machines Inc (NASDA ...

Key Takeaways PFE stock fell after 2026 view missed expectations. Revenues expected to be $59.5-$62.5B on modest growth.Pfizer expects lower COVID sales and deal dilution to cut 2026 adjusted earnings to $2.80-$3.00.PFE faces a 2026-2030 patent cliff, but oncology drugs and new launches are driving non-COVID growth.Pfizer (PFE) stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations.Pfizer expects total revenues for ...

Key Takeaways MRK faces major headwinds as Keytruda, its top revenue driver, nears the loss of exclusivity in 2028.Declining Gardasil sales due to weak China demand and lower vaccine uptake in Japan ail MRK.MRK is counting on Capvaxive, Winrevair and strategic cost savings to help counter patent/pricing headwinds.Merck (MRK) is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, the most significant being the upcoming loss of exclusivity (“LOE”) fo ...

PresentationThank you for standing by. My name is Jayel, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin business update. [Operator Instructions] I would now like to turn the conference over to Traci McCarthy, Head of Investor Relations. You may begin. Perhaps, your line is on mute, Traci.Traci McCartyGroup Vice President Thank you, Jayel, and good morning, everyone. Thank you for joining us to discuss BioMarin's acquisition of Amicus Therapeutics ...

Key Takeaways MRNA will get up to $54.3M from CEPI to run a pivotal phase III study of its mRNA-1018 H5 flu vaccine.Moderna's phase III will test safety and immunogenicity in the U.S. and U.K., starting in early 2026.MRNA plans to set aside 20% of H5 vaccine output for low and middle-income countries if approved.Moderna (MRNA) announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in funding to support a pivotal phase III study evaluating its investigatio ...

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. ...